[HTML][HTML] Head to head evaluation of second generation ALK inhibitors brigatinib and alectinib as first-line treatment for ALK+ NSCLC using an in silico systems biology …
E Carcereny, A Fernández-Nistal, A López, C Montoto… - Oncotarget, 2021 - ncbi.nlm.nih.gov
Abstract Around 3–7% of patients with non-small cell lung cancer (NSCLC), which represent
85% of diagnosed lung cancers, have a rearrangement in the ALK gene that produces an …
85% of diagnosed lung cancers, have a rearrangement in the ALK gene that produces an …
Molecular dynamics validation of crizotinib resistance to ALK mutations (L1196M and G1269A) and identification of specific inhibitors
N Nagasundaram, CR Wilson Alphonse… - Journal of Cellular …, 2017 - Wiley Online Library
Anaplastic lymphoma kinase (ALK) positive non‐small cell lung cancer (NSCLC) patients
are mostly treated with ALK tyrosine kinase inhibitors (TKIs). Crizotinib is the first generation …
are mostly treated with ALK tyrosine kinase inhibitors (TKIs). Crizotinib is the first generation …
[HTML][HTML] Prediction of ALK mutations mediating ALK-TKIs resistance and drug re-purposing to overcome the resistance
Background Alectinib has shown a greater efficacy to ALK-rearranged non-small-cell lung
cancers in first-line setting; however, most patients relapse due to acquired resistance, such …
cancers in first-line setting; however, most patients relapse due to acquired resistance, such …
[HTML][HTML] A computational examination of the therapeutic advantages of fourth-generation ALK inhibitors TPX-0131 and repotrectinib over third-generation lorlatinib for …
A Balasundaram, GPC Doss - Frontiers in Molecular Biosciences, 2024 - frontiersin.org
Background: In non-small-cell lung cancer (NSCLC), a pivotal factor in promoting cancer
development is the rearrangement in the anaplastic lymphoma kinase ALK gene, resulting …
development is the rearrangement in the anaplastic lymphoma kinase ALK gene, resulting …
[HTML][HTML] Insight into systematic development of ALK (anaplastic lymphoma kinase) inhibitors towards NSCLC treatment
Among cancer-related disorders, lung carcinoma is one of the leading causes of mortality.
Anaplastic lymphoma kinase (ALK) belongs to tyrosine kinase receptor family and exhibits …
Anaplastic lymphoma kinase (ALK) belongs to tyrosine kinase receptor family and exhibits …
[HTML][HTML] Mitoxantrone and abacavir: An ALK protein-targeted in silico proposal for the treatment of non-small cell lung cancer
JE Faya Castillo, RJ Zapata Dongo, PA Wong Chero… - Plos one, 2024 - journals.plos.org
Non-small cell lung cancer (NSCLC) is a type of lung cancer associated with translocation of
the EML4 and ALK genes on the short arm of chromosome 2. This leads to the development …
the EML4 and ALK genes on the short arm of chromosome 2. This leads to the development …
[HTML][HTML] The emerging therapeutic landscape of ALK inhibitors in non-small cell lung cancer
V Gristina, M La Mantia, F Iacono, A Galvano, A Russo… - Pharmaceuticals, 2020 - mdpi.com
The treatment of metastatic non-small cell lung cancer (NSCLC) has undergone a paradigm
shift over the last decade. Better molecular characterization of the disease has led to the …
shift over the last decade. Better molecular characterization of the disease has led to the …
The potent ALK inhibitor brigatinib (AP26113) overcomes mechanisms of resistance to first-and second-generation ALK inhibitors in preclinical models
S Zhang, R Anjum, R Squillace, S Nadworny… - Clinical Cancer …, 2016 - AACR
Purpose: Non–small cell lung cancers (NSCLCs) harboring ALK gene rearrangements
(ALK+) typically become resistant to the first-generation anaplastic lymphoma kinase (ALK) …
(ALK+) typically become resistant to the first-generation anaplastic lymphoma kinase (ALK) …
[HTML][HTML] Treating ALK-positive non-small cell lung cancer
DC Ziogas, A Tsiara, G Tsironis, M Lykka… - Annals of …, 2018 - ncbi.nlm.nih.gov
Targeting genomic alterations, such as epidermal growth factor receptor (EGFR) mutations
and anaplastic lymphoma kinase (ALK) gene rearrangements, have radically changed the …
and anaplastic lymphoma kinase (ALK) gene rearrangements, have radically changed the …
Identification of Novel Alectinib-Resistant ALK Mutation G1202K with Sensitization to Lorlatinib: A Case Report and in silico Structural Modelling
Background Drug resistance caused by G1202R/G1202del mutation in anaplastic
lymphoma kinase (ALK) represents a great challenge in the clinic. The effect of other …
lymphoma kinase (ALK) represents a great challenge in the clinic. The effect of other …